Avash News: Mohammad-Karim Rezaei, Director General of the company’s Research and Development Center, said that the medicine, named “Midoness,” is prescribed for the treatment of AML.
He noted that the drug is also effective in treating a rare disease called Systemic Mastocytosis, adding that patients diagnosed with this disease usually have a short lifespan, and Midoness is currently the only approved medicine in the world for its treatment.
The drug can extend the average lifespan of patients to around five years, giving them the opportunity to be added to the list of candidates for bone marrow transplantation.
Systemic Mastocytosis is a neoplastic (cancer-like) disease in which the number of mast cells in the body increases abnormally, leading to their accumulation in various tissues such as the bone marrow, liver, skin, spleen, and intestines. In most patients, a mutation occurs in a gene called KIT, which causes the continuous activation of mast cell growth receptors—meaning the cells keep proliferating without external signals.
Rezaei added that the domestically produced medicine is significantly more affordable than its foreign counterpart.
“The imported version of the medicine costs around 1.5 billion tomans per unit, while the domestic version costs about 25 million tomans per month—a substantial difference,” he said.
